Drugs / HSK40118
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06050980 | Mar 2023 → Aug 2025 overdue | non-small cell lung carcinoma | Haisco Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSK40118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06050980 ↗ |
| Route | Oral | “Oral administration, QD” NCT06050980 ↗ |